Our biotech company, MultiplexDX, aims to use the latest advance in molecular biology and the power of transcriptomics to develop novel molecular diagnostic tools for diagnosing diseases such as cancer.
After successfully completing our EIC Accelerator grant, we are planning a large-scale retrospective validation of our molecular diagnostic test for breast cancer called Multiplex8+. This test uses advances in spatial biology to both visualize and sequence a panel of RNA based biomarkers to differentiate subtypes of breast cancer, stratify patients into prognostic risk groups, and evaluate the sensitivity or resistance to diverse treatments ranging from chemotherapies, targeted therapies, and novel antibody drug-conjugates.
Our overarching aim is to augment the patient journay with our precision oncology tools to facilitate personalized, effective, and life-saving treatment plans.
We offer a great career with development opportunities in a highly motivating and professional environment. You may be looking for a new career path or simply looking to contribute to a small, hard-working organization with the ambition to make a difference.
You will be offered the opportunity to spearhead the next ground-breaking diagnostic technologies involving RNA-based next-generation sequencing.
The job will be challenging and rewarding at the same time. You will have world-class colleagues, flexible working hours, and a negotiable salary commensurate to your qualifications (starting from €2500/ month).
Please send the application including your CV or resume with the names of 2 references and a cover letter to career@multiplexdx.com.
Your application will be treated in accordance with our policies for processing of personal data and the General Data Protection Regulation of the EU.
Peter Kilian
COO
Ilkovičova 8
84104 Bratislava, Slovakia
career@multiplexdx.com
www.multiplexdx.com
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter